B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.
B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.
